Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for exceptional importation and sale are called "designated drugs".

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The key to a good experience with these medications (as with any prescription drug) is working with a prescribing doctor who listens to and collaborates with their patients. Stimulants Work Best ...

Please note that classification priorities can change quickly, and the expected dates of completion are only indicative at the time of publication. There is high demand for classification assessments, ...

via REUTERS Semaglutide — the active ingredient in Ozempic and Wegovy — is part of a class of drugs that mimic the body’s natural GLP-1 hormone, making users feel fuller for longer.

Scientists compared 175 different health outcomes between those who took GLP-1 drugs to those who took traditional diabetes medications such as Jardiance. “We saw skyrocketing utilization of GLP ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...